Get regular updates to your inbox.
Uplizna (inebilizumab-cdon) works to treat people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether such patients carry genetic variants linked to poor responses to other B-cell depleting therapies, new trial data show. An analysis of N-MOmentum Phase 2/3 data found that the approved therapy was as effective…
Constipation may be linked with pain due to nerve cell damage in people diagnosed with neuromyelitis optica spectrum disorder (NMOSD) and the related disorder myelin oligodendrocyte glycoprotein antibody disease (MOGAD), a study suggests. “Both symptoms were significantly more common among patients with a history of myelitis,” the researchers wrote of constipation…
People with neuromyelitis optica spectrum disorder (NMOSD), but lacking anti-AQP4 and anti-MOG antibodies, show no signs of damage to astrocytes — nervous system cells attacked in NMOSD — when compared to those with anti-AQP4 antibodies. Those findings from a recent study suggest that the mechanisms underlying NMOSD symptoms in…
Rituximab worked better than other treatments at preventing relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against aquaporin-4 (AQP-4), according to a recent Chinese report. As a first-line therapy for the autoimmune disease, Rituximab outperformed both azathioprine and mycophenolate mofetil (MMF) in relapse prevention, the…
The European Commission has approved Uplizna (inebilizumab-cdon) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4-IgG). The approval covers all member states in the European Union, as well as Iceland, Liechtenstein, and Norway. Horizon Therapeutics, the company marketing Uplizna,…
A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…
Giving immunosuppressive therapy to patients with antibodies against aquaporin-4 protein (AQP4) and optic neuritis but no symptoms may help resolve observed lesions and prevent a relapse of neuromyelitis optica spectrum disorder (NMOSD), a case report suggests. The case study, “Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder,” was…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…
An analysis of pharmacological data supports the observed clinical efficacy of Soliris (eculizumab) in significantly reducing relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) given the therapy in the PREVENT Phase 3 clinical trial. At its approved dose, Soliris led to rapid, sustained, and complete suppression…
A case report has detailed the clinical journeys of two identical twin sisters’ simultaneous diagnosis with neuromyelitis optica spectrum disorder (NMOSD), a rare occurrence. NMOSD was last reported in identical twin sisters in 1938, but those girls’ symptoms started two years apart, unlike the present case. The case report,…
Get regular updates to your inbox.